<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113564</url>
  </required_header>
  <id_info>
    <org_study_id>CNS7056-016</org_study_id>
    <nct_id>NCT04113564</nct_id>
  </id_info>
  <brief_title>Absolute Oral Bioavailability of Remimazolam</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, 2-way Crossover Study to Compare the Relative Bioavailability of Orally Administered Remimazolam to an Intravenous Formulation in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paion UK Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Paion UK Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, single-dose, 2-way crossover study to compare the relative&#xD;
      bioavailability of orally administered remimazolam to an intravenous formulation in healthy&#xD;
      volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 3, 2015</start_date>
  <completion_date type="Actual">November 20, 2015</completion_date>
  <primary_completion_date type="Actual">November 20, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute oral bioavailability of remimazolam</measure>
    <time_frame>Day 1 (pre-dode) to Day 3</time_frame>
    <description>Single-dose bioavailability of an oral formulation of remimazolam relative to an IV formulation of remimazolam in healthy male and female subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma concentration (Cmax)</measure>
    <time_frame>Day 1 (pre-dode) to Day 3</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma concentration (Tmax)</measure>
    <time_frame>Day 1 (pre-dode) to Day 3</time_frame>
    <description>Time to attain maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC0-t)</measure>
    <time_frame>Day 1 (pre-dode) to Day 3</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 up to the time of the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (T1/2)</measure>
    <time_frame>Day 1 (pre-dode) to Day 3</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL/F)</measure>
    <time_frame>Day 1 (pre-dode) to Day 3</time_frame>
    <description>Apparent oral clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Vz/F)</measure>
    <time_frame>Day 1 (pre-dode) to Day 3</time_frame>
    <description>Apparent volume of distribution at terminal phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of Treatment-emergent adverse events</measure>
    <time_frame>Day 1 (pre-dode) to Day 3</time_frame>
    <description>Incidences of Treatment-emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Bioavailability</condition>
  <arm_group>
    <arm_group_label>IV remimazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV remimazolam administration of 0.025 mg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral remimazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral remimazolam Administration of 0.14 mg/kg Body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam</intervention_name>
    <arm_group_label>IV remimazolam</arm_group_label>
    <arm_group_label>Oral remimazolam</arm_group_label>
    <other_name>CNS7056</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing to participate in the study, willing to give written informed consent prior to&#xD;
             the initiation of any protocol-specific procedures, and willing to comply with the&#xD;
             study restrictions.&#xD;
&#xD;
          2. Had to be able to speak, read, and understand English sufficiently to allow completion&#xD;
             of all study assessments.&#xD;
&#xD;
          3. Gender : males and/or females&#xD;
&#xD;
          4. Age : 18 - 55 years, inclusive&#xD;
&#xD;
          5. Body mass index (BMI) : 18.0 - 32.0 kg/m2&#xD;
&#xD;
          6. Weight : â‰¥50 kg&#xD;
&#xD;
          7. Healthy status was defined by the absence of evidence of any clinically significant,&#xD;
             in the opinion of the Investigator, active or chronic disease following a detailed&#xD;
             medical and surgical history, a complete physical examination including vital signs,&#xD;
             12-lead ECG, hematology, clinical chemistry, serology, and urinalysis.&#xD;
&#xD;
          8. Ability and willingness to abstain from alcohol, caffeine, and xanthine-containing&#xD;
             beverages or food (eg, coffee, tea, cola, chocolate, energy drinks) from 48 hours (2&#xD;
             days) prior to admission to the clinical facility on Day -1 until study discharge.&#xD;
&#xD;
          9. All values for hematology and for clinical chemistry tests of blood and urine within&#xD;
             the normal range or showing no clinically relevant deviations as judged by the&#xD;
             Investigator.&#xD;
&#xD;
         10. Females of childbearing potential and males and their female partner(s) of&#xD;
             childbearing potential had to agree to use 2 forms of contraception, 1 of which had to&#xD;
             be a barrier method, during the study and for 90 days after the last drug&#xD;
             administration. Acceptable barrier forms of contraception were condom and diaphragm.&#xD;
             Acceptable non-barrier forms of contraception for this study were an intrauterine&#xD;
             device (IUD) and/or spermicide.&#xD;
&#xD;
         11. For females: a negative pregnancy test at Screening and Day -1.&#xD;
&#xD;
         12. Postmenopausal females: defined as 12 months with no menses prior to Screening and a&#xD;
             serum follicle stimulating hormone (FSH) &gt;40 IU/L at Screening.&#xD;
&#xD;
         13. All non-regular medication (including over-the-counter [OTC] medication, health&#xD;
             supplements, and herbal remedies such as St. John's Wort extract) must have been&#xD;
             stopped at least 14 days prior to admission to the clinical research center. An&#xD;
             exception was made for paracetamol (acetaminophen), which was allowed up to admission&#xD;
             to the clinical research center.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who were pregnant or lactating.&#xD;
&#xD;
          2. Males with female partners who were pregnant or lactating.&#xD;
&#xD;
          3. Use of any investigational drug or device within 30 days of the first dose of study&#xD;
             medication.&#xD;
&#xD;
          4. Any disease which, in the opinion of the Investigator, posed an unacceptable risk to&#xD;
             the subjects.&#xD;
&#xD;
          5. Known allergy, hypersensitivity or prior intolerance to benzodiazepine derivates or&#xD;
             flumazenil, or a medical condition such that these agents were contraindicated.&#xD;
&#xD;
          6. The use of tobacco products within 60 days prior to the first drug administration.&#xD;
&#xD;
          7. Routine or chronic use of more than 3 grams of acetaminophen daily.&#xD;
&#xD;
          8. Strenuous activity, sunbathing and contact sports within 48 hours (2 days) prior to&#xD;
             admission to the clinical facility and for the duration of the study.&#xD;
&#xD;
          9. History of donation of more than 450 mL of blood within 60 days prior to dosing in the&#xD;
             clinical research center or planned donation before 30 days had elapsed since intake&#xD;
             of study drug.&#xD;
&#xD;
         10. Plasma or platelet donation within 7 days of dosing and throughout the entire study.&#xD;
&#xD;
         11. History of alcohol consumption exceeding 2 standard drinks per day on average (1&#xD;
             standard drink = 10 grams of alcohol). Alcohol consumption was prohibited from 48&#xD;
             hours prior to admission to the clinical facility and throughout the entire study&#xD;
             until discharge.&#xD;
&#xD;
         12. Positive screening test for hepatitis B surface antigen (HBsAg), anti-hepatitis C&#xD;
             virus (HCV) antibodies, or anti-human immunodeficiency virus (HIV) 1 and 2 antibodies.&#xD;
&#xD;
         13. Positive results for drugs of abuse, including cotinine, in the urine at Screening or&#xD;
             Day -1.&#xD;
&#xD;
         14. Positive results for alcohol abuse, as determined by alcohol breath test, at Screening&#xD;
             or Day -1.&#xD;
&#xD;
         15. Inability to be venipunctured or tolerate venous access as determined by the&#xD;
             Investigator or designee.&#xD;
&#xD;
         16. History of clinically significant, recent/current and nonremote suicidal ideations or&#xD;
             suicide attempts that, in the opinion of the Investigator, posed an unacceptable risk&#xD;
             to the subject for participating in the study.&#xD;
&#xD;
         17. Any major surgery within 4 weeks of study drug administration. NOTE: Any&#xD;
             parameter/test could be repeated at the Investigator's discretion during Screening&#xD;
             and/or on Day -1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shawn Searle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences (PRA) - Early Development Services (EDS)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 27, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

